NCT04739306View on ClinicalTrials.gov

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

PHASE3CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

October 14, 2022

Study Completion Date

April 24, 2023

Conditions
Diabetic Macular Edema (DME)
Interventions
BIOLOGICAL

CT-P42

2mg/0.05 mL by Intravitreal injection

BIOLOGICAL

Eylea

2mg/0.05 mL by Intravitreal injection

Trial Locations (1)

Unknown

II. Ocna klinika SZU, F.D.Roosevelt Hospital, Banská Bystrica

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04739306 - Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter